Yanfeng Zou

Prof. Yanfeng Zou

Anhui Medical University

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2022 in Science of The Total Environment
Verified
Journal Article
Closed access
CZChunxia Zhai
Chunxia Zhai
DHDingtao Hu
Dingtao Hu
GYGuanghui Yu
Guanghui Yu
WHWanqin Hu
Wanqin Hu
QZQiqun Zong
Qiqun Zong
YZYanfeng Zou
Yanfeng Zou

9 June 2022 in Scottish Medical Journal
Verified
Journal Article
Closed access
ZLZhen Li
Zhen Li
YWYu-Hua Wang
Yu-Hua Wang
LWLin-Lin Wang
Lin-Lin Wang
DHDing-Tao Hu
Ding-Tao Hu
YTYing Teng
Ying Teng
YZYanfeng Zou
Yanfeng Zou
Background and Aims: This updated meta-analysis aimed to further quantify the risk of endometrial, ovarian, and breast cancer in patients with polycystic ovary syndrome (PCOS), thus providing updated and more reliable estimates. Methods and Results: We identified relevant articles by searching electronic databases of PubMed, Embase, Web of Science, and Chinese Biological Medical Literature (CBM) published up to March 20, 2021. The pooled effect estimates and their 95% confidence intervals ( CIs) were calculated using the random-effect model or the fixed-effect model. A total of 26 eligible studies were included. We found that PCOS was significantly associated with endometrial cancer (odds ratios [ OR]: 3.66, 95% CI: 2.05–6.54, P < 0.001), but not with ovarian or breast cancer ( OR: 1.23, 95% CI: 0.99–1.53, P = 0.059; OR: 0.94, 95% CI: 0.78–1.14, P = 0.551, respectively). However, in subgroups of high-quality studies, cohort studies, younger women (54 years or less or premenopausal), and studies with unadjusted body mass index (BMI), PCOS patients had a significantly higher risk of ovarian cancer. Conclusion: These results indicated that PCOS is a significant risk factor for endometrial cancer independent of BMI, but not for breast cancer. PCOS may increase the risk of ovarian cancer in younger women.

1 September 2023 in Preventive Medicine
Verified
Journal Article
Closed access
HSHongyu Sun
Hongyu Sun
YLYuqi Liu
Yuqi Liu
YXYing Xu
Ying Xu
XGXingyu Gong
Xingyu Gong
CZChunxia Zhai
Chunxia Zhai
YZYanfeng Zou
Yanfeng Zou

12 May 2023 in Public Health
Verified
Journal Article
Closed access
GYGuanghui Yu
Guanghui Yu
XGXingyu Gong
Xingyu Gong
YXYing Xu
Ying Xu
HSHongyu Sun
Hongyu Sun
YLYuqi Liu
Yuqi Liu
YZYanfeng Zou
Yanfeng Zou

27 September 2010 in Cancer Investigation
Verified
Journal Article
Closed access
PDF file
YZYanfeng Zou
Yanfeng Zou
FYFeng-Lai Yuan
Feng-Lai Yuan
XFXiao-Liang Feng
Xiao-Liang Feng
JTJin-Hui Tao
Jin-Hui Tao
NDNing Ding
Ning Ding
FWFang Wang
Fang Wang
The aim of our meta-analysis was to assess the association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk. Eleven studies that included data from 2,743 cases and 2,195 controls were identified. When all groups were pooled, we did not detect the association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk. In the subgroup analysis, we detected the association of NFKB1 -94ins/delATTG promoter polymorphism with cancer in Caucasian population. The association also was found in Asian population. This meta-analysis demonstrates the association of NFKB1 -94ins/delATTG promoter polymorphism with cancer in Caucasian and Asian populations, and this association is ethno-specific.

16 June 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
QLQiu-Yue Lou
Qiu-Yue Lou
ZLZhen Li
Zhen Li
YTYing Teng
Ying Teng
QXQiao-Mei Xie
Qiao-Mei Xie
MZMan Zhang
Man Zhang
YZYanfeng Zou
Yanfeng Zou